PRM160 - IMPACT OF POST-PROGRESSION OLARATUMAB (OLARA) MONOTHERAPY FOLLOWING DOXORUBICIN (DOX) MONOTHERAPY ON OVERALL SURVIVAL (OS).
Oct 1, 2018, 00:00
10.1016/j.jval.2018.09.2280
https://www.valueinhealthjournal.com/article/S1098-3015(18)35582-7/fulltext
Title :
PRM160 - IMPACT OF POST-PROGRESSION OLARATUMAB (OLARA) MONOTHERAPY FOLLOWING DOXORUBICIN (DOX) MONOTHERAPY ON OVERALL SURVIVAL (OS).
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(18)35582-7&doi=10.1016/j.jval.2018.09.2280
First page :
Section Title :
Open access? :
No
Section Order :
1634